New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?

Elevated low-density lipoprotein cholesterol (LDL-C) is a principally modifiable cause of atherosclerotic cardiovascular disease; accordingly, recent European and US multisociety dyslipidaemia guidelines emphasise the importance of lowering LDL-C to reduce cardiovascular risk. This review provides perspectives on established and emerging agents that reduce LDL-C to help providers synthesize the abundance of new evidence related to prevention of cardiovascular disease. We provide hypothetical cases of patients with different cardiovascular risk factors and medical histories to illustrate application of current lipid-lowering guidelines in various clinical settings.

Source: Atherosclerosis - December 21, 2020 Category: Cardiology Authors: Dan Atar, J. Wouter Jukema, Bart Molemans, Pam R. Taub, Shinya Goto, Fran çois Mach, Cesar CerezoOlmos, James Underberg, Anthony Keech, Lale Tokgözoğlu, Marc P. Bonaca Tags: Review article Source Type: research